# Ipamorelin Research: Mechanism, the Human Trial, and Stack Comparisons

> Ipamorelin research, lead-first: GHS-R1a mechanism, the human PK data, the failed Phase 2 trial, and how it compares to CJC-1295, sermorelin, and tesamorelin — fully cited.

## Before the details

Here is the **Ipamorelin** research in plain language. Ipamorelin is a man-made peptide that flips a switch — the ghrelin receptor — on the pituitary gland, which then releases a burst of growth hormone. What makes it interesting to scientists is that it does this cleanly: lots of growth hormone, almost no cortisol or prolactin [1]. The strongest data are old and preclinical (rats and pigs in the late 1990s), plus one human study that measured how fast it clears the blood [2]. The one human trial that tested whether it *helps* anything — recovery of bowel function after surgery — did not work [3]. The newest published animal study, in ferrets in 2024, showed it blunted chemotherapy weight loss but did nothing for nausea [5]. Below, each major finding gets its own section, with the species and dose stated and the source cited.

## What is ipamorelin peptide

Ipamorelin is a synthetic pentapeptide — sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular formula C₃₈H₄₉N₉O₅, ~711.9 Da, CAS 170851-70-4. It was derived from the earlier peptide GHRP-1 by removing a central Ala-Trp dipeptide [1]. The non-natural amino acid Aib (alpha-aminoisobutyric acid) at position 1, plus the D-form residues, make it resistant to the enzymes that would otherwise chew it up. Functionally it is a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) — it mimics the natural hormone ghrelin at that receptor to release growth hormone [1]. It is wholly synthetic and is not a peptide the human body makes.

## Mechanism: a clean growth-hormone pulse

Ipamorelin binds GHS-R1a (the ghrelin receptor) on pituitary somatotrophs — the GH-producing cells — and triggers GH release through the Gq/PLC pathway, which raises intracellular calcium [1]. The headline result from the founding 1998 study: in primary rat pituitary cells, anaesthetized rats, and conscious swine, ipamorelin released GH as potently as GHRP-6 (swine ED50 2.3 ± 0.03 nmol/kg vs 3.9 nmol/kg) but did **not** raise ACTH or cortisol above the GHRH baseline even at more than 200× the GH ED50 [1]. That is the selectivity that defines the molecule.

The GH it releases then feeds the liver's IGF-1 axis — though in short rodent studies IGF-1 is not always elevated, suggesting some effects are local and pulse-driven [4]. Ipamorelin also has peripheral actions: a direct, GH-independent insulinotropic effect on pancreatic islet tissue [13], and engagement of the brain's appetite circuitry typical of the ghrelin-agonist class [15].

## The human pharmacokinetic data

The cleanest human dataset is a population PK/PD study in healthy male volunteers (n=8 per dose level) given five 15-minute IV infusions spanning 4.21–140.45 nmol/kg [2]. Kinetics were linear and dose-proportional, with a terminal half-life of approximately 2 hours, clearance 0.078 L/h/kg, and a steady-state volume of distribution 0.22 L/kg [2]. The growth-hormone response arrived as a single discrete pulse peaking around 0.67 h — about 40 minutes — after dosing [2]. This is one of the only human ipamorelin datasets in existence, and it is the basis for nearly every "how long does it last" statement on this site.

## The one human efficacy trial — and it failed

Ipamorelin's defining human anchor is a single Phase 2 RCT (NCT00672074) in 114 adults undergoing bowel resection, given 0.03 mg/kg IV twice daily for up to 7 days [3]. It **missed its primary endpoint**: median time to first tolerated meal was 25.3 h with ipamorelin versus 32.6 h with placebo, which did not reach statistical significance (p=0.15) [3]. On safety, treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific safety signal emerged in that short perioperative window [3]. The honest reading: efficacy was not demonstrated, and the lack of any approval reflects failed efficacy programs, not merely incomplete development.

## Preclinical efficacy: bone, body weight, and the 2024 ferret study

In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily for 15 days) dose-dependently raised the longitudinal bone-growth rate from 42 µm/day on vehicle to 44, 50, and 52 µm/day — with no change in total IGF-1, IGFBPs, or bone-turnover markers, pointing to a partly local, GH-pulse-driven skeletal effect [4]. NN703, an oral analog derived directly from ipamorelin, produced significant body-weight gain over 14 days in rats, confirming the class alters body composition via sustained GH-axis activation [7].

The most recent published in-vivo ipamorelin study, in 2024, used a ferret model: intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48–72 h), but had no anti-emetic effect on either acute or delayed emesis [5]. It reduced chemotherapy-associated weight loss through a peripheral mechanism while doing nothing for nausea — the freshest defensible finding in the literature.

## Ipamorelin cjc-1295

Ipamorelin (a ghrelin-receptor peptide) and CJC-1295 (a GHRH analog) release GH through two different, complementary doors: ipamorelin via GHS-R1a, CJC-1295 via the GHRH receptor's cAMP pathway [1]. The rationale for pairing them is synergy — combining a GHRP with GHRH can produce GH release greater than the arithmetic sum of each alone, shown for the related peptide hexarelin plus GHRH in healthy men (true synergism, P=0.001) [9]. A 2026 orthopaedic review reports that CJC-1295 + ipamorelin improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss model in mice, while stressing that the evidence is limited to animal studies [18]. Critically, the combination itself has not been tested in a controlled human outcome trial — its support is single-agent pharmacology, not combination trials [3].

## What is cjc 1295 ipamorelin

"CJC-1295 ipamorelin" (sometimes written without the hyphen) refers to the popular research combination of two distinct peptides — it is not a single approved product, and this site otherwise documents pure ipamorelin. CJC-1295 is a long-acting GHRH analog; ipamorelin is a selective ghrelin-receptor GH secretagogue [1]. Together they are promoted for sleep, recovery, and body composition, but the pairing's evidence base is extrapolated from each agent's separate pharmacology plus animal work [18]. No completed human trial has tested the combination for any clinical outcome [3].

## Does cjc-1295 ipamorelin work

For raising GH acutely, the mechanisms are real: GHRP + GHRH co-administration produces synergistic GH release in humans, and prolonged GHRP-6 infusion more than doubled integrated GH while augmenting responses to GHRH boluses [10]. For *clinical outcomes* — fat loss, muscle, anti-aging — the answer is that it has not been demonstrated in controlled human trials [3]. A 2026 narrative review found CJC-1295 + ipamorelin improved muscle tetanic tension in a murine model but explicitly noted evidence is limited to animal studies [18]. So: a measurable hormonal effect, yes; proven human benefit, not yet.

## Ipamorelin vs sermorelin

Ipamorelin and sermorelin sit on opposite sides of the GH-release pathway. Ipamorelin is a ghrelin-receptor (GHS-R1a) peptide [1]; sermorelin is a GHRH analog (it mimics growth-hormone-releasing hormone). They are sometimes combined precisely because a GHRP and a GHRH analog hit different receptors and can act synergistically [9]. The key safety distinction for this site: ipamorelin has never been an approved drug [3], whereas sermorelin had a different regulatory history as a GHRH analog. On selectivity, ipamorelin's signature is sparing cortisol and prolactin [1]; that is a property of the ghrelin-receptor mechanism, not the GHRH mechanism sermorelin uses.

## Ipamorelin vs tesamorelin

Tesamorelin, like sermorelin, is a GHRH analog — it works on the GHRH receptor, not the ghrelin receptor that ipamorelin targets [1]. The mechanistic contrast is the same GHRP-versus-GHRH split: ipamorelin releases GH via GHS-R1a with a cortisol-sparing profile [1], while tesamorelin acts through the GHRH/cAMP pathway. From the safety lens this site leads with, the relevant fact is regulatory: ipamorelin has no approved indication and a failed Phase 2 trial [3], placing it in the non-approved-peptide group that recent reviews flag for absent long-term safety data [17]. Comparisons of GH secretagogues as a class consistently note that approved agents carry safety profiles from large trials that ipamorelin simply does not have [17].

## Combination and class pharmacology

Several human studies clarify how GHRP-class peptides like ipamorelin behave when stacked. Chronic GHRP-2 or GHRH administration over 7–30 days converted an additive GHRP-2 + GHRH response into a synergistic one in younger and older adults, with the pattern depending on which agent was given chronically first [11]. And GHRP + GHRH synergy persisted even under high somatostatin tone that largely blunted GHRH alone — illustrating the somatostatin-overcoming advantage of the combination [12]. These are class-level principles (studied with hexarelin, GHRP-2, and GHRP-6, not ipamorelin specifically) that frame why ipamorelin is paired with GHRH analogs, while underscoring that ipamorelin's own combination data in humans are absent [3].

---

A tolerability-first read of the ipamorelin record — the failed Phase 2 endpoint, the two-hour half-life, and the class cardiotoxicity signal logged before anything flattering, every figure carried back to the study that measured it; a reference console, never a clinic, a prescriber, or a store.